Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
br Secretase modulators a loss
2022-08-02

γ-Secretase modulators: a loss of pharmacology? A lack of translation from in vitro to in vivo pharmacology is an unresolved issue among most GSMs. R-flurbiprofen was tested in clinical trials, however, it did not achieve statistical significance on either of its primary endpoints – cognition or
-
The gene structures of cGalR
2022-08-02

The gene structures of cGalR2 and cGalR2-L were determined by in silico comparison with the chicken genomic DNA sequences retrieved from the Ensembl database. Both cGalR2 and cGalR2-L genes are composed of two coding exons, separated by single introns of 0.9kb (cGalR2) or 3kb (cGalR2-L) locating wit
-
As shown in Table the results of individual
2022-08-02

As shown in Table 3, the results of individual prediction modeling with chemicals at 0.4 mM, 0.6 mM, and 0.8 mM would lead to lesser sensitivity of 60.0%, 65.0%, and 65.0%, respectively, in microsome-unused group, and 85.0%, 85.0%, and 90.0%, in microsome-used group. If we consider only the results
-
Albumin is the major carrier of
2022-08-02

Albumin is the major carrier of free fatty acids (FFAs) in plasma [59], and harbours seven binding sites that are common to FFAs with a range of chain-lengths (C10-C18) across its three domains (Fig. 1a) [60,61]. In vitro, saturated, mono- and poly-unsaturated FFAs, with chain lengths ranging from C
-
br Materials and methods br Acknowledgments We
2022-08-02

Materials and methods Acknowledgments We are grateful for financial support from the National Natural Science Foundation of China (Grants No. 81661148046 and 81773762, China) and the “Personalized Medicines—Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research
-
TAK-875 Receptor interactions and binding mode of
2022-08-02

Receptor interactions and binding mode of in hGPR40 were determined by docking studies. The compound was docked in the rebuilt co-crystal structure of hGPR40 (PDB ID: ) using MOE for loop modeling and energy minimization and Glide for molecular docking. The docking site used for the docking simulat
-
br Materials and methods br Results and discussion In
2022-08-02

Materials and methods Results and discussion In order to identify genes required for photoautotrophic growth, we screened a random insertion mutant library of Synechocystis 6803 and obtained many mutants with impaired photoautotrophic growth. About 6000 random insertion colonies of the mutant
-
Introduction The Antiretroviral Therapy ART in the last deca
2022-08-02

Introduction The Antiretroviral Therapy (ART), in the last decade, has been providing a better treatment for the Human Immunodeficiency Virus 1 (HIV) infection, by reducing its viral load to undetectable levels and recovering the immune system. In fact, according to the last data from UNAIDS the mo
-
The combination of HIV antigen and
2022-08-02

The combination of HIV antigen and antibody testing with the fourth generation immunoassays shortens the window MK-8245 sale for HIV by detecting HIV antigen, which appears in the blood before seroconversion [3,5,11,12]. Analysis of the seroconversion panels indicated the Elecsys® HIV Duo assay has
-
GSK has also been used as PET
2022-08-01

GSK-189254 has also been used as PET radiotracer (in the form of [11C]-GSK-189254, also used as [11C]-AZ12807110 by Jucaite et al. (Jucaite et al., 2013)) to assess H3R occupancy (Ashworth et al., 2010), and is currently used in an image-based phase I clinical trial study for investigating GSK-23951
-
br Acknowledgments br Introduction Lung
2022-08-01

Acknowledgments Introduction Lung cancer is a common but extremely perilous cancer, with approximately 733,000 new incidences reported annually in China [1]. Lung cancer ranks highest in the causes of tumor-related mortality, accounting for approximately one quarter of all cancer deaths [2]. N
-
Newly identified evidence has put immune
2022-08-01

Newly identified evidence has put immune checkpoint inhibitors into the spotlight. However, even though they have been reported to achieve optimistic outcomes [67], there is still a provocative question about their limitations [68]. The solid evidence above has provided us with translational values
-
Different crystal structures of both HOs were reported and
2022-07-30

Different crystal structures of both HOs were reported and showed that the three-dimensional structures of proteins (HO-1: PDB code 1N45, HO-2: PDB code 2QPP) are predominantly in an α-helical conformation, with the heme packed between two helices (distal and proximal), and present a remarkable str
-
br Background To treat chronic
2022-07-30

Background To treat chronic HCV genotype (GT) 1-infected patients, telaprevir (TLP) or boceprevir (BOC), first generation protease inhibitors (PIs), were used in combination with pegylated-interferon (PEG-IFN) and ribavirin (RBV) triple therapy [1], [2]. The main weaknesses of the first-generatio
-
The replacement of the P butyl
2022-07-30

The replacement of the P-butyl urea cap with sulfonamide derived cap had a profound effect on binding. Compound obtained by the replacement of -butyl urea P cap of compound with sulfonamide demonstrated a =34nM, a fifteen folds improvement in potency. Similarly replacement of P-butyl cap in the P
8001 records 412/534 page Previous Next First page 上5页 411412413414415 下5页 Last page